Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Radiation Therapy Following Surgery to Remove Brain Metastases

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center Identifier:
First received: November 1, 1999
Last updated: October 28, 2015
Last verified: July 2012

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy after surgery to remove brain metastases may decrease the amount of radiation required to treat brain metastases.

PURPOSE: Pilot trial to study the effectiveness of radiation therapy following surgery to remove brain metastases.

Condition Intervention
Metastatic Cancer
Procedure: surgical procedure
Radiation: radiation therapy
Radiation: stereotactic radiosurgery

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pilot Study of Adjuvant Fractionated Stereotactic Radiotherapy Following Surgical Removal of Cerebral Metastases

Resource links provided by NLM:

Further study details as provided by Jonsson Comprehensive Cancer Center:

Enrollment: 20
Study Start Date: March 1997
Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES: I. Assess the safety and tolerability of focal stereotactic radiotherapy to the surgical bed following excision of cerebral metastases, as an alternative to whole brain irradiation. II. Measure the local relapse rate at the surgical site after surgery and stereotactic radiotherapy in patients with cerebral metastases. III. Measure the regional relapse rate, in the brain but away from the treated site, following treatment in these patients.

OUTLINE: All patients undergo surgical removal of their cerebral metastases followed by adjuvant fractionated stereotactic radiotherapy daily for 5 days. Patients are given up to 5 weeks following surgery to recover and reach the required performance status. Radiotherapy must commence within 6 weeks of surgery. Patients are followed at 2 weeks after treatment, monthly for 6 months, every 3 months for the next 18 months, every 6 months for the next year, and then annually for years 3-5.

PROJECTED ACCRUAL: There will be 20-40 patients accrued into this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed cerebral metastases post surgical resection
  • No greater than 3 cerebral metastases postresection
  • Gross resection at operation as documented in operation note and postoperative MRI Patients must have current surgical sites that have not been previously irradiated
  • No other indication for whole brain irradiation (i.e., multiple untreated metastases not suitable for single fraction stereotactic radiotherapy, leptomeningeal disease)
  • Age: 18 and over
  • Karnofsky 60-100%
  • Life expectancy: At least 3 months
  • Prior or concurrent required steroids allowed
  • Prior stereotactic radiotherapy of cerebral metastases allowed provided no prior irradiation of current surgical sites
  • Prior surgery of cerebral metastases allowed

Exclusion Criteria:

  • severe asthma requiring therapy
  • allergy to iodine or contrast media
  • pregnant
  • concurrent chemotherapy
  • prior whole brain irradiation or focal irradiation to current sites of disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00003320

United States, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States, 90095-1781
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Study Chair: Judith M. Ford, MD, PhD Jonsson Comprehensive Cancer Center
  More Information

Responsible Party: Jonsson Comprehensive Cancer Center Identifier: NCT00003320     History of Changes
Other Study ID Numbers: CDR0000066270
P30CA016042 ( US NIH Grant/Contract Award Number )
Study First Received: November 1, 1999
Last Updated: October 28, 2015

Keywords provided by Jonsson Comprehensive Cancer Center:
tumors metastatic to brain

Additional relevant MeSH terms:
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes processed this record on April 28, 2017